title: Association between apolipoprotein E4 and rehabilitation outcome in hospitalized ischemic stroke patients.
abstract: OBJECTIVE
  To determine the value of apolipoprotein E4 (APOE*E4) allele in predicting discharge impairment and disability in ischemic stroke patients after acute rehabilitation.
  
  
  METHODS
  Prospective study comparing results of rehabilitation in patients with different APOE genotypes.
  
  
  METHODS
  Acute neurologic rehabilitation department in Israel.
  
  
  METHODS
  One hundred one consecutive patients 75 years old or less with a first ischemic stroke.
  
  
  METHODS
  Not applicable.
  
  
  METHODS
  Impairment, as measured by the National Institutes of Health Stroke Scale (NIHSS), and disability, as assessed with the FIM trade mark instrument.
  
  
  RESULTS
  On admission, there was no significant difference in the FIM or NIHSS measurements between the apo E4 group and other patients, but the prevalence of aphasia was 2.07 times more frequent in those with the APOE*E4 genotype (95% confidence interval, 0.98-4.4). A logistic regression model demonstrated that score measurements on admission were highly predictive of the NIHSS score at discharge (receiver operator curve=96.1%), whereas the presence of the APOE*E4 genotype did not add significantly to the model in predicting poorer rehabilitation treatment outcome as measured by the FIM or the NIHSS.
  
  
  CONCLUSIONS
  The presence of the apo E4 allele did not predict a poorer outcome of rehabilitation treatment after ischemic stroke, but it was associated with an increased prevalence of aphasia. Further studies are warranted to confirm this association.
authors.affiliation: Lowenstein Rehabilitation Center, Ra'anana, Israel.
authors.forename: Iuly
authors.initials: I
authors.lastname: Treger
authors.forename: Paul
authors.initials: P
authors.lastname: Froom
authors.forename: Haim
authors.initials: H
authors.lastname: Ring
authors.forename: Gideon
authors.initials: G
authors.lastname: Friedman
mesh_terms: D000203:Activities of Daily Living; D000208:Acute Disease; D000368:Aged; D000704:Analysis of Variance; D001037:Aphasia / Q000209:etiology; D053327:Apolipoprotein E4; D001057:Apolipoproteins E / Q000097:blood* / Q000235:genetics; D002545:Brain Ischemia / Q000150:complications*; D004185:Disability Evaluation; D005260:Female; D005838:Genotype; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007557:Israel; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D012047:Rehabilitation Centers; D012720:Severity of Illness Index; D016037:Single-Blind Method; D020521:Stroke / Q000097:blood* / Q000209:etiology; D000071939:Stroke Rehabilitation; D016896:Treatment Outcome
chemical_list: D053327:Apolipoprotein E4; D001057:Apolipoproteins E